1
|
Puliatti S, Eissa A, Ferretti S, Micali S, Bianchi G. Fluorescence laser confocal microscopy: a glimpse from the future. Minerva Urol Nephrol 2023; 75:786-787. [PMID: 38126294 DOI: 10.23736/s2724-6051.23.05641-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Affiliation(s)
- Stefano Puliatti
- Department of Urology, University of Modena and Reggio Emilia, Modena, Italy -
| | - Ahmed Eissa
- Department of Urology, University of Modena and Reggio Emilia, Modena, Italy
- Department of Urology, Faculty of Medicine, University of Tanta, Tanta, Egypt
| | - Stefania Ferretti
- Department of Urology, University of Modena and Reggio Emilia, Modena, Italy
| | - Salvatore Micali
- Department of Urology, University of Modena and Reggio Emilia, Modena, Italy
| | - Giampaolo Bianchi
- Department of Urology, University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
2
|
Tsaur I, van den Bergh RCN, Soeterik T, Thomas A, Brandt MP, Zattoni F, Dal Moro F, Morlacco A, Collavino J, Ploussard G, Surcel C, Mirvald C, Carmona O, Rosenzweig B, Ruckes C, Heisinger T, Heidegger I, Gandaglia G, Dotzauer R. Predictors of Unfavorable Pathology in Patients with Incidental (pT1a-T1b) Prostate Cancer. Eur Urol Focus 2022; 8:1599-1606. [PMID: 35317972 DOI: 10.1016/j.euf.2022.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 01/23/2022] [Accepted: 03/08/2022] [Indexed: 01/25/2023]
Abstract
BACKGROUND Incidental prostate cancer (IPCa) is encountered in 10% of surgical procedures for benign prostatic obstruction (BPO). Identification of patients with underlying detrimental prostate cancer is paramount for tailored treatment decision-making, but guideline recommendations for this setting are lacking. OBJECTIVE To highlight clinical and histological characteristics related to BPO surgery that may predict IPCa with unfavorable pathology. DESIGN, SETTING, AND PARTICIPANTS We included men with IPCa who underwent radical prostatectomy (RP) in the short term after IPCa diagnosis. Two cohorts were built according to final pathology for the RP specimen: unfavorable pathology (International Society of Urological Pathology [ISUP] grade group [GG] ≥3 and/or ≥pT3a and/or pN1) versus favorable pathology. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS We performed multivariate regression analysis for the endpoint, which was unfavorable pathology for the RP specimen. Using the model estimates for prostate-specific antigen (PSA), ISUP GG, age, and prostate volume, we established a model for estimating the risk of unfavorable histopathology. RESULTS AND LIMITATIONS Overall, 112 patients were included in the final assessment. On multivariate analysis, PSA (odds ratio [OR] 1.083, 95% confidence interval [CI] 1.003-1.170; p = 0.042), ISUP GG for the specimen from BPO surgery (OR 3.090; 95% CI 1.129-8.457; p = 0.028), and age (OR 1.121, 95% CI 1.026-1.225; p = 0.012) were independent predictors for unfavorable histopathology. On receiver operating characteristic analysis, the area under the curve was 0.751. A novel calculator was developed to predict adverse pathology for men with IPCa. The study is limited by its retrospective design. CONCLUSIONS For men with IPCa, PSA before surgery for BPO, ISUP GG, and age are independent predictors of unfavorable disease. Our results might improve preoperative risk assessment for patient counseling. PATIENT SUMMARY We developed a novel calculator to estimate the risk of underlying detrimental disease in men diagnosed with prostate cancer at surgery for benign prostatic obstruction.
Collapse
Affiliation(s)
- Igor Tsaur
- Department of Urology and Pediatric Urology, University Medicine Mainz, Mainz, Germany.
| | | | - Timo Soeterik
- Department of Urology, St Antonius Hospital, Utrecht, The Netherlands
| | - Anita Thomas
- Department of Urology and Pediatric Urology, University Medicine Mainz, Mainz, Germany
| | - Maximilian P Brandt
- Department of Urology and Pediatric Urology, University Medicine Mainz, Mainz, Germany
| | - Fabio Zattoni
- Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padua, Padua, Italy
| | - Fabrizio Dal Moro
- Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padua, Padua, Italy
| | - Alessandro Morlacco
- Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padua, Padua, Italy
| | - Jeanlou Collavino
- Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padua, Padua, Italy
| | - Guillaume Ploussard
- Department of Urology, La Croix du Sud Hospital, Toulouse, France; Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France
| | - Christian Surcel
- Center of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | - Christian Mirvald
- Center of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | - Orel Carmona
- Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - Barak Rosenzweig
- Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Christian Ruckes
- Interdisciplinary Centre for Clinical Trials, University Medical Centre, Johannes Gutenberg University, Mainz, Germany
| | - Tatjana Heisinger
- Department of Urology, Medical University Innsbruck, Innsbruck, Austria
| | - Isabel Heidegger
- Department of Urology, Medical University Innsbruck, Innsbruck, Austria
| | - Giorgio Gandaglia
- Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Robert Dotzauer
- Department of Urology and Pediatric Urology, University Medicine Mainz, Mainz, Germany
| | | |
Collapse
|
3
|
Søndergaard MEJ, Lode K, Husebø SE, Dalen I, Kjosavik SR. Men's perception of information and psychological distress in the diagnostic phase of prostate cancer: a comparative mixed methods study. BMC Nurs 2022; 21:266. [PMID: 36180907 PMCID: PMC9526317 DOI: 10.1186/s12912-022-01047-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Accepted: 09/19/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Previous studies indicate that men experience frustration and uncertainty when confronted with an elevated prostate specific antigen (PSA) test and during further diagnostics for prostate cancer. The novel Stockholm3 test is an algorithm-based test that combines plasma protein biomarkers, genetic markers and clinical variables in predicting the risk of PCa. The test was introduced in a western part of Norway as a new tool for detecting prostate cancer. This study aimed to explore and compare men's perception of information and possible experience of distress between a PSA group and a Stockholm3 group during the diagnostic phase of prostate cancer. METHODS This study is a part of the trailing research evaluating the impact of the change from PSA to Stockholm3. It is a multicenter study using a comparative mixed method design. Data were collected in a PSA group (n = 130) and a Stockholm3 group (n = 120) between 2017 and 2019. Quantitative data were collected using questionnaires and qualitative data were collected using semi-structured interviews (n = 20). The quantitative and qualitative data were analysed and compared separately and then merged in a side-by-side discussion. The study adheres to the GRAMMS guidelines for reporting mixed-methods research. RESULTS Compared with the PSA group, men in the Stockholm3 group reported that the information from the general practitioners was better. Similarly, men in the Stockholm3 group were more likely to indicate that they had received sufficient information regarding how examinations would be conducted. No differences were found between the groups regarding waiting time and distress. Three themes emerged from the qualitative analysis of the two groups: "Information affects the experience of comprehension", "Stepping into the world of the healthcare system", and "Periodically feelings of distress". CONCLUSION The Stockholm3 test may facilitate the provision of information to patients. However, some patients in both groups experienced distress and would benefit from more information and additional support from healthcare professionals. Routines that ensure sufficient information from the interdisciplinary healthcare team should be of priority during the diagnostic phase of prostate cancer in order to provide patients with predictability and to avoid unnecessary distress.
Collapse
Affiliation(s)
- Maja Elisabeth Juul Søndergaard
- Department of Surgery, Stavanger University Hospital, Postboks 8100, 4068, Stavanger, Norway. .,Research Group of Nursing and Healthcare Sciences, Stavanger University Hospital, Postboks 8100, 4068, Stavanger, Norway. .,Faculty of Health Sciences, University of Stavanger, Kjell Arholms Hus, postboks 8600, 4036, Stavanger, Norway.
| | - Kirsten Lode
- Research Group of Nursing and Healthcare Sciences, Stavanger University Hospital, Postboks 8100, 4068, Stavanger, Norway.,Faculty of Health Sciences, University of Stavanger, Kjell Arholms Hus, postboks 8600, 4036, Stavanger, Norway
| | - Sissel Eikeland Husebø
- Department of Surgery, Stavanger University Hospital, Postboks 8100, 4068, Stavanger, Norway.,Research Group of Nursing and Healthcare Sciences, Stavanger University Hospital, Postboks 8100, 4068, Stavanger, Norway.,Faculty of Health Sciences, University of Stavanger, Kjell Arholms Hus, postboks 8600, 4036, Stavanger, Norway
| | - Ingvild Dalen
- Department of Research, Section of Biostatistics, Stavanger University Hospital, Postboks 8100, 4068, Stavanger, Norway
| | - Svein Reidar Kjosavik
- Faculty of Health Sciences, University of Stavanger, Kjell Arholms Hus, postboks 8600, 4036, Stavanger, Norway.,The General Practice and Care Coordination Research Group, Stavanger University Hospital, Postboks 8100, 4068, Stavanger, Norway
| |
Collapse
|